Company intelligence / Profile preview

ViVerita Discovery

Ownership: Private
Development stage: Other

Overview

ViVerita Discovery uses a proprietary in vivo CRISPR-based platform to identify and validate novel therapeutic targets for precision oncology. The company has recently entered into a strategic research collaboration with Boehringer Ingelheim to accelerate the discovery of new cancer targets. No clinical results have been reported yet, as the company's programs remain at the preclinical stage focused on target validation and early drug development.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Boehringer Ingelheim

Beyond the preview

Go deeper on ViVerita Discovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViVerita Discovery.

Explore the full profile